Improving the quality and efficiency of follow-up after curative treatment for breast cancer - rationale and study design of the MaCare trial

被引:18
作者
Kimman, Merel L. [1 ]
Voogd, Adri C.
Dirksen, Carmen D.
Falger, Paul
Hupperets, Pierre
Keymeulen, Kristien
Hebly, Marlene
Dehing, Cary
Lambin, Philippe
Boersma, Liesbeth J.
机构
[1] Maastro Clin, Maastricht, Netherlands
[2] Maastricht Univ, Dept GROW MAASTRO, Maastricht, Netherlands
[3] Maastricht Univ, Dept Epidemiol, Maastricht, Netherlands
[4] Univ Hosp Maastricht, Dept Clin Epidemiol & Med Technol Assessment, Maastricht, Netherlands
[5] Univ Hosp Maastricht, Dept Med Psychol, Maastricht, Netherlands
[6] Univ Hosp Maastricht, Dept Med Oncol, Maastricht, Netherlands
[7] Univ Hosp Maastricht, Dept Surg, Maastricht, Netherlands
[8] Univ Hosp Maastricht, Dept Radiat Oncol, Maastricht, Netherlands
关键词
D O I
10.1186/1471-2407-7-1
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Background: After curative treatment for breast cancer women frequently attend scheduled follow-up examinations. Usually the follow-up is most frequent in the first 2-3 years ( 2-4 times a year); thereafter the frequency is reduced to once a year in most countries. Its main aim is to detect local disease recurrence, or a second primary breast cancer, but also to provide information and psychosocial support. However, the cost-effectiveness of these frequent visits is under much debate, leading to a search for less intensive and more cost-effective follow-up strategies. In this paper the design of the MaCare trial is described. This trial compares the cost-effectiveness of four follow-up strategies for curatively treated breast cancer patients. We investigate the costs and effects of nurse-led telephone follow-up and a short educational group programme. Methods/design: The MaCare trial is a multi centre randomised clinical trial in which 320 breast cancer patients are randomised into four follow-up strategies, focussed on the first 18 months after treatment: 1) standard follow-up; 2) nurse-led telephone follow-up; 3) arm 1 with the educational group programme; 4) arm 2 with the educational group programme. Data is collected at baseline and 3, 6, 12 and 18 months after treatment. The primary endpoint of the trial is cancer-specific quality of life as measured by the global health/QoL scale of the EORTC QLQ-C30. Secondary outcomes are perceived feelings of control, anxiety, patients' satisfaction with follow-up and costs. A cost-effectiveness analysis will be performed from a societal perspective. Discussion: Reduced follow-up strategies for breast cancer have not yet been widely applied in clinical practice. Improvement of psychosocial support and information to patients could lead to a better acceptance of reduced follow-up. The MaCare trial combines a reduced follow-up strategy with additional psychosocial support. Less frequent follow-up can reduce the burden on medical specialists and costs. The educational group programme can improve QoL of patients, but also less frequent follow-up can improve QoL by reducing the anxiety experienced for each follow-up visit. Results of the trial will provide knowledge on both costs and psychosocial aspects regarding follow-up and are expected in 2009.
引用
收藏
页数:7
相关论文
共 34 条
[1]   THE EUROPEAN-ORGANIZATION-FOR-RESEARCH-AND-TREATMENT-OF-CANCER QLQ-C30 - A QUALITY-OF-LIFE INSTRUMENT FOR USE IN INTERNATIONAL CLINICAL-TRIALS IN ONCOLOGY [J].
AARONSON, NK ;
AHMEDZAI, S ;
BERGMAN, B ;
BULLINGER, M ;
CULL, A ;
DUEZ, NJ ;
FILIBERTI, A ;
FLECHTNER, H ;
FLEISHMAN, SB ;
DEHAES, JCJM ;
KAASA, S ;
KLEE, M ;
OSOBA, D ;
RAZAVI, D ;
ROFE, PB ;
SCHRAUB, S ;
SNEEUW, K ;
SULLIVAN, M ;
TAKEDA, F .
JOURNAL OF THE NATIONAL CANCER INSTITUTE, 1993, 85 (05) :365-376
[2]  
Allen Alison, 2002, Eur J Oncol Nurs, V6, P155, DOI 10.1054/ejon.2002.0175
[3]  
[Anonymous], EUROPEAN J ONCOLOGIC
[4]  
[Anonymous], EUROPEAN J ONCOLOGY
[5]  
[Anonymous], 2004, HANDLEIDING KOSTENON
[6]   Recurrence rates after treatment of breast cancer with standard radiotherapy with or without additional radiation. [J].
Bartelink, H ;
Horiot, J ;
Poortmans, P ;
Struikmans, H ;
Van den Bogaert, W ;
Barillot, I ;
Fourquet, A ;
Borger, J ;
Jager, J ;
Hoogenraad, W ;
Collette, L ;
Pierart, M .
NEW ENGLAND JOURNAL OF MEDICINE, 2001, 345 (19) :1378-1387
[7]   IS THERE A NEED TO FOLLOW-UP CANCER-PATIENTS [J].
BRADA, M .
EUROPEAN JOURNAL OF CANCER, 1995, 31A (05) :655-657
[8]   Patient initiated follow up of breast cancer [J].
Brown, L ;
Payne, S ;
Royle, G .
PSYCHO-ONCOLOGY, 2002, 11 (04) :346-355
[9]   Group and individual treatment strategies for distress in cancer patients [J].
Clark, MM ;
Bostwick, JM ;
Rummans, TA .
MAYO CLINIC PROCEEDINGS, 2003, 78 (12) :1538-1543
[10]   Patient's needs and preferences in routine follow-up after treatment for breast cancer [J].
de Bock, GH ;
Bonnema, J ;
Zwaan, RE ;
de Velde, CJH ;
Kievit, J ;
Stiggelbout, AM .
BRITISH JOURNAL OF CANCER, 2004, 90 (06) :1144-1150